Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03407001 · ClinicalTrials.gov registry record · Early Phase 1
Contrast Enhanced Ultrasound With Lumason in Detecting Liver Cancer in Participants With Cirrhosis
A Early Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 9
- Enrollment target
NCT03407001: Completed Early Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT03407001 is a Early Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 9 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03407001, a Early Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This early phase I trial studies how well contrast enhanced ultrasound with sulfur hexafluoride lipid microspheres (Lumason) works in detecting liver cancer in participants with cirrhosis. Contrast enhanced-ultrasounds use contrast agents, such as Lumason, that are injected into a vein in order to help certain organs and tissues show up more clearly on scans. Contrast enhanced ultrasound with Lumason may help doctors more easily find liver cancer compared to ultrasounds without contrast agent.
Primary Outcome
The study will estimate the sensitivity of ultrasound (US) and CEUS in patients with detectable lesions on magnetic resonance imaging (MRI). The analysis will be conducted at the patient level with a binary outcome of 0 if the patient has no detectable lesions and 1 if the patient has one or more detectable lesions. The study will use McNemar's test to compare US vs. CEUS in patients with any detectable lesions on MRI. The test assesses whether the two tests have equivalent marginal probabilitie
Interventions
- PROCEDURE Contrast-Enhanced Ultrasound
- DRUG Sulfur Hexafluoride Lipid Microspheres
- PROCEDURE Ultrasound
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2018-01-12 |
| Est. Completion | 2020-09-15 |
| Phase | Early Phase 1 |
What the finished NCT03407001 record still lists
NCT03407001 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 3 interventions - of which Contrast-Enhanced Ultrasound is the first listed.
NCT03407001 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03407001 about?
NCT03407001 is a clinical study titled "Contrast Enhanced Ultrasound With Lumason in Detecting Liver Cancer in Participants With Cirrhosis". This early phase I trial studies how well contrast enhanced ultrasound with sulfur hexafluoride lipid microspheres (Lumason) works in detecting liver cancer in participants with cirrhosis. Contrast enhanced-ultrasounds use contrast agents, such as Lumason, that are injected into a vein in order to h...
What is the current status of trial NCT03407001?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2018-01-12. Estimated completion is 2020-09-15.
What interventions are being tested in trial NCT03407001?
The interventions under investigation include: Contrast-Enhanced Ultrasound (PROCEDURE), Sulfur Hexafluoride Lipid Microspheres (DRUG), Ultrasound (PROCEDURE).
Who is sponsoring clinical trial NCT03407001?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03407001's enrollment target sits among peer trials
9 1746th of 2000 higher than 219 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI